234 related articles for article (PubMed ID: 22499046)
1. [Retrospective analysis of progression to multiple myeloma or related disorders in 114 patients with monoclonal gammopathy of undetermined significance in a single institute].
Yokota S; Urasaki Y; Nakamura Y; Bessho M
Rinsho Ketsueki; 2012 Mar; 53(3):303-9. PubMed ID: 22499046
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up of patients with monoclonal gammopathy of undetermined significance after kidney transplantation.
Naina HV; Harris S; Dispenzieri A; Cosio FG; Habermann TM; Stegall MD; Dean PG; Prieto M; Kyle RA; Rajkumar SV; Leung N
Am J Nephrol; 2012; 35(4):365-71. PubMed ID: 22473253
[TBL] [Abstract][Full Text] [Related]
3. Incidence and evolution of monoclonal gammopathy of undetermined significance (MGUS) in Greece.
Anagnostopoulos A; Evangelopoulou A; Sotou D; Gika D; Mitsibounas D; Dimopoulos MA
Ann Hematol; 2002 Jul; 81(7):357-61. PubMed ID: 12185503
[TBL] [Abstract][Full Text] [Related]
4. [Multiple myeloma after monoclonal gammopathy of uncertain significance. Study of 10 patients].
Salgado C; Bladé J; López-Guillermo A; Cervantes F; Montserrat E; Rozman C
Sangre (Barc); 1993 Oct; 38(5):371-4. PubMed ID: 8140498
[TBL] [Abstract][Full Text] [Related]
5. [Monoclonal gammopathy of undetermined significance--potential risk factor of multiple myeloma].
Stelmach-Gołdyś A; Czarkowska-Paczek B
Przegl Lek; 2012; 69(5):194-6. PubMed ID: 23050415
[TBL] [Abstract][Full Text] [Related]
6. Arterial and venous thrombosis in patients with monoclonal gammopathy of undetermined significance: incidence and risk factors in a cohort of 1491 patients.
Za T; De Stefano V; Rossi E; Petrucci MT; Andriani A; Annino L; Cimino G; Caravita T; Pisani F; Ciminello A; Torelli F; Villivà N; Bongarzoni V; Rago A; Betti S; Levi A; Felici S; Gentilini F; Calabrese E; Leone G;
Br J Haematol; 2013 Mar; 160(5):673-9. PubMed ID: 23240810
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression.
Kyle RA; Rajkumar SV
Br J Haematol; 2007 Dec; 139(5):730-43. PubMed ID: 18021088
[TBL] [Abstract][Full Text] [Related]
8. Pathogenesis and progression of monoclonal gammopathy of undetermined significance.
Bladé J; Rosiñol L; Cibeira MT; de Larrea CF
Leukemia; 2008 Sep; 22(9):1651-7. PubMed ID: 18668131
[TBL] [Abstract][Full Text] [Related]
9. Epidemiology of Monoclonal Gammopathy of Undetermined Significance (MGUS): The experience from the specialized registry of hematologic malignancies of Basse-Normandie (France).
Cabrera Q; Macro M; Hebert B; Cornet E; Collignon A; Troussard X
Cancer Epidemiol; 2014 Aug; 38(4):354-6. PubMed ID: 24880205
[TBL] [Abstract][Full Text] [Related]
10. [Monoclonal gammopathy of undetermined significance (MGUS) in Mexican mestizos: one institution's experience].
Ruiz-Delgado GJ; Gómez Rangel JD
Gac Med Mex; 2004; 140(4):375-9. PubMed ID: 15456147
[TBL] [Abstract][Full Text] [Related]
11. Association between metformin use and progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans with diabetes mellitus: a population-based retrospective cohort study.
Chang SH; Luo S; O'Brian KK; Thomas TS; Colditz GA; Carlsson NP; Carson KR
Lancet Haematol; 2015 Jan; 2(1):e30-6. PubMed ID: 26034780
[TBL] [Abstract][Full Text] [Related]
12. The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma.
Sigurdardottir EE; Turesson I; Lund SH; Lindqvist EK; Mailankody S; Korde N; Björkholm M; Landgren O; Kristinsson SY
JAMA Oncol; 2015 May; 1(2):168-74. PubMed ID: 26181017
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Kyle RA; Rajkumar SV
Hematol Oncol Clin North Am; 2007 Dec; 21(6):1093-113, ix. PubMed ID: 17996590
[TBL] [Abstract][Full Text] [Related]
14. Fracture risk in monoclonal gammopathy of undetermined significance.
Melton LJ; Rajkumar SV; Khosla S; Achenbach SJ; Oberg AL; Kyle RA
J Bone Miner Res; 2004 Jan; 19(1):25-30. PubMed ID: 14753733
[TBL] [Abstract][Full Text] [Related]
15. Secondary monoclonal gammopathy of undetermined significance is frequently associated with high response rate and superior survival in patients with plasma cell dyscrasias.
Zou D; An G; Zhu G; Wang J; Shi L; Meng H; Xu Y; Sui W; Deng S; Zhan F; Qiu L
Biol Blood Marrow Transplant; 2014 Mar; 20(3):319-25. PubMed ID: 24296491
[TBL] [Abstract][Full Text] [Related]
16. Determining the clinical significance of monoclonal gammopathy of undetermined significance: a SEER-Medicare population analysis.
Go RS; Gundrum JD; Neuner JM
Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):177-186.e4. PubMed ID: 25445471
[TBL] [Abstract][Full Text] [Related]
17. Bone-marrow immunophenotypic analysis allows the identification of high risk of progression and immune condition-related monoclonal gammopathy of undetermined significance.
Jerez A; Ortuño FJ; Osma Mdel M; Español I; González AD; Roldán V; de Arriba F; Vicente V
Ann Med; 2009; 41(7):547-58. PubMed ID: 19634064
[TBL] [Abstract][Full Text] [Related]
18. A long-term study of prognosis in monoclonal gammopathy of undetermined significance.
Kyle RA; Therneau TM; Rajkumar SV; Offord JR; Larson DR; Plevak MF; Melton LJ
N Engl J Med; 2002 Feb; 346(8):564-9. PubMed ID: 11856795
[TBL] [Abstract][Full Text] [Related]
19. Obesity and the Transformation of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma: A Population-Based Cohort Study.
Chang SH; Luo S; Thomas TS; O'Brian KK; Colditz GA; Carlsson NP; Carson KR
J Natl Cancer Inst; 2017 May; 109(5):. PubMed ID: 28040690
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal gammopathy of undetermined significance does not affect outcomes in patients undergoing solid organ transplants.
Jimenez-Zepeda VH; Heilman RL; Engel RA; Carey EJ; Freeman C; Rakela J; Mulligan DC; Fonseca R; Stewart AK
Transplantation; 2011 Sep; 92(5):570-4. PubMed ID: 21712755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
